Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells

University of North Carolina (UNC)

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Other: IFNbeta-1b

Study type: Interventional

Funder types: Other

Identifiers

NCT00630721

07-0941

Details and patient eligibility

About

Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces tolerizing effect on DC-dependent T-cell differentiation in patients with MS by inducing the expression of SOCS3 in DCs.

Enrollment: 56 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Confirmed diagnosis of MS
• Age 18-60 years, inclusive
• Expanded disability status of 0-6.5
• Give written informed consent prior to any testing under this protocol

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

56 participants in 1 patient group

IFNbeta-1b

Other group

Description:

no drug was given under study. patients already taking IFNbeta-1b were enrolled for blood draw only.

Treatment:

Other: IFNbeta-1b